Plus Therapeutics Inc.
Chart
Good to know: Investing in stocks tends to provide long-term positive returns, but it also involves risks. You can lose some or all of your investment. Past performance of this stock is not a reliable indicator of future results. Data from external providers has not been altered by Saxo. See full data disclaimer
About Plus Therapeutics Inc.
Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).
/ 
Others were interested in
See all stocksFrequently asked questions
To buy Plus Therapeutics Inc. stock, open a Saxo account and fund it. With SaxoInvestor or SaxoTrader, you can easily search for Plus Therapeutics Inc. by name or ticker, choose the number of shares, and place your order.
The ticker symbol for Plus Therapeutics Inc. is PSTV:xnas. You can use this code to quickly find the stock in Saxo’s platforms and track its price and performance.
Plus Therapeutics Inc. has its primary listing on NASDAQ. You can trade Plus Therapeutics Inc. with a Saxo account, alongside thousands of other stocks worldwide.
Yes, Plus Therapeutics Inc. is available to trade on SaxoInvestor and SaxoTraderGO. You can buy shares directly and include Plus Therapeutics Inc. as part of a broader investment portfolio. Explore our SaxoInvestor platform.
Learn more about investing and trading at Saxo’s educational content hub. Explore portfolio strategies, types of stocks, diversification, and valuation measures— so you can make more informed decisions when considering shares like Plus Therapeutics Inc..